Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care01:30

Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care

14
A healthcare provider can diagnose a urinary tract infection (UTI) through several methods:Medical History and Symptoms: The provider will take a detailed medical history and ask about symptoms such as frequent urination, burning sensation during urination, and lower abdominal pain.Urinalysis: A clean-catch urine sample is collected in a sterile container and tested for the presence of bacteria, white blood cells (leukocytes), nitrites, blood, and protein. The presence of leukocytes and...
14
Urinary Tract Calculi III: Medical Management01:30

Urinary Tract Calculi III: Medical Management

9
The diagnosis of renal calculi involves several imaging techniques, including non-contrast CT scans and ultrasound. These methods help visualize kidney stones, assess their size and location, and detect possible obstructions. Additionally, Measuring urine pH is useful for diagnosing specific stone types, such as struvite (alkaline pH) and uric acid stones (acidic pH). Cystine stones are primarily linked to cystinuria, a genetic condition. A urinalysis helps detect blood in the urine (hematuria)...
9
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

186
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
186
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

181
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
181
Imaging Studies VI: Voiding Cystourethrography and Cystography01:22

Imaging Studies VI: Voiding Cystourethrography and Cystography

10
Voiding Cystourethrography (VCUG) and Cystography are specialized radiographic procedures used to examine the structure and function of the bladder and urethra.Voiding Cystourethrography (VCUG)A Voiding Cystourethrogram (VCUG) is a diagnostic imaging procedure that assesses the anatomy and function of the lower urinary tract. It focuses on the bladder, bladder neck, and urethra, helping detect abnormalities such as vesicoureteral reflux (VUR)—the backward or reverse flow of urine into the...
10
Urinary Tract Calculi VI: Surgical Management01:25

Urinary Tract Calculi VI: Surgical Management

8
Procedures for Kidney StonesMedical intervention is necessary when kidney stones or renal calculi are too large to pass spontaneously (typically greater than 5 millimeters) when stones are accompanied by symptomatic infection (such as fever or pyelonephritis), when they impair kidney function, or when they cause persistent symptoms like severe pain, nausea, or urinary retention. Additionally, patients with only one kidney or those who cannot be treated with medical management also require...
8

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mental health disorders following nephrectomy for renal cell carcinoma: a national study.

BJU international·2026
Same author

Understanding the utilization of genetic counseling and testing among patients with prostate cancer.

The Canadian journal of urology·2026
Same author

Impact of Elevated C-Reactive Protein on Survival Outcomes of Patients with Small Renal Masses: A Retrospective Multicenter Analysis.

Current oncology (Toronto, Ont.)·2026
Same author

Contemporary Validation of the Renal Cell Carcinoma Inflammatory Score (RISK) for Preoperative Prognostication in Non-Metastatic Renal Cell Carcinoma.

Urology practice·2026
Same author

Evaluating the Diagnostic Performance of Clear Cell Likelihood Score in Predicting Clear Cell Renal Cell Carcinoma Among Patients Younger Than 50 Years.

JCO oncology practice·2026
Same author

C-Reactive Protein/Albumin Ratio (CAR)-Integrated IMDC Model Improves Risk Stratification in Metastatic Renal Cell Carcinoma.

Cancers·2026

Related Experiment Video

Updated: Jul 12, 2025

Evaluation of Biomaterials for Bladder Augmentation using Cystometric Analyses in Various Rodent Models
10:19

Evaluation of Biomaterials for Bladder Augmentation using Cystometric Analyses in Various Rodent Models

Published on: August 9, 2012

19.3K

Long-Term Cost Analysis of Third-Line Treatment Options for Overactive Bladder.

Mary Pelling1, Jessica Hammett1, Dattatraya Patil1

  • 1Emory University School of Medicine, Atlanta, Georgia.

Urology Practice
|November 2, 2023
PubMed
Summary

Sacral neuromodulation (SNM) is the most cost-effective third-line treatment for overactive bladder (OAB) over 15 years. It offers the lowest total net payment and patient contribution compared to other OAB therapies.

Keywords:
botulinum Aoveractive bladderposterior tibial nerve stimulationsacral neuromodulationurinary incontinence

More Related Videos

Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing
05:25

Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing

Published on: August 14, 2019

19.2K
Nerve-sparing Mid-urethral Obstruction NeMO in Female Small Rodents
07:42

Nerve-sparing Mid-urethral Obstruction NeMO in Female Small Rodents

Published on: April 25, 2017

9.7K

Related Experiment Videos

Last Updated: Jul 12, 2025

Evaluation of Biomaterials for Bladder Augmentation using Cystometric Analyses in Various Rodent Models
10:19

Evaluation of Biomaterials for Bladder Augmentation using Cystometric Analyses in Various Rodent Models

Published on: August 9, 2012

19.3K
Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing
05:25

Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing

Published on: August 14, 2019

19.2K
Nerve-sparing Mid-urethral Obstruction NeMO in Female Small Rodents
07:42

Nerve-sparing Mid-urethral Obstruction NeMO in Female Small Rodents

Published on: April 25, 2017

9.7K

Area of Science:

  • Urology
  • Health Economics
  • Medical Economics

Background:

  • Overactive bladder (OAB) is a condition affecting millions, necessitating effective third-line treatments.
  • Evaluating the long-term economic impact of OAB treatments is crucial for patient and healthcare system planning.

Purpose of the Study:

  • To analyze and compare the long-term costs of third-line treatments for overactive bladder (OAB).
  • To determine the most cost-effective third-line therapeutic option for OAB over a 15-year period.

Main Methods:

  • Retrospective analysis of insurance claims data (2015-2020) from MarketScan (MKS) and Medicare supplemental (MDC) databases.
  • Included patients aged 18+ with OAB diagnosis receiving percutaneous tibial nerve stimulation, sacral neuromodulation (SNM), or botulinum A therapy.
  • Extracted and aggregated patient-level costs, including total net payment and patient contribution, over an estimated 15-year period.

Main Results:

  • Sacral neuromodulation (SNM) demonstrated the lowest total net payment ($5,179.10 MKS, $6,099.00 MDC) and patient contribution ($59.10 MKS, $60.00 MDC) over 15 years.
  • Percutaneous tibial nerve stimulation was the most expensive treatment option.
  • Botulinum A represented an intermediate cost between SNM and percutaneous tibial nerve stimulation.

Conclusions:

  • Sacral neuromodulation (SNM) is the most cost-effective third-line treatment for overactive bladder (OAB) based on long-term cost analysis.
  • The findings support SNM as a preferred economic choice for managing OAB when initial therapies fail.